BioCorRx (OTC: BICX) Medical innovation in treating addiction

 

 

 

 

 

 

 

BioCorRx (OTC: BICX) Interview with CEO Brady Granier, discussing the company's technology for treating opioid, alcohol and other addictions with Naltrexone implants. Brady discusses the company's business model, progress towards FDA approval, and upcoming launch of a promising weight-loss program utilizing the Naltrexone implant.

 

Investor Presentation

  . . .

This content is available to members only.

If you are an existing member, please LOGIN

Note a member? Sign up for a FREE trial account ($195 per month value), and get immediate access. Free offer expires June 15, 2019.

Register New Account

Free Membership

.

Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2
subscribe@wallstreetreporter.com.